Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
October 2016
-
Media ReleaseNovartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbustersQ3 net sales (-1% cc[2] and USD) broadly in line with prior year due to strong performance of Growth Products Gilenya (USD 790 million, +15% cc) continued double-digit growth Cosentyx (USD 301…
-
Media ReleaseNovartis erzielt im dritten Quartal solide Ergebnisse, wobei die Wachstumsprodukte[1] den Verlust des Patents für Gleevec wettmachen; mehrere positive Daten für potenzielle BlockbusterDank starker Performance der Wachstumsprodukte bleibt der Nettoumsatz im dritten Quartal (-1% kWk[2] und USD) weitgehend unverändert gegenüber dem Vorjahreszeitraum Gilenya (USD 790 Millionen, +…
-
Media ReleaseNovartis a réalisé un troisième trimestre solide, les produits de croissance[1] ayant compensé l'expiration du brevet de Glivec; plusieurs résultats positifs concernant des blockbusters potentielsChiffre d'affaires net du T3 (-1% tcc[2] et USD) largement comparable au T3 2015 grâce à l'excellente performance des produits de croissance Gilenya (USD 790 millions, +15% tcc) a poursuivi sa…
-
Media ReleaseAlcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meetingAlcon to host first live training program on the use of the CyPass® Micro-Stent, a minimally invasive glaucoma surgical device to treat cataract patients with mild to moderate primary open-angle…
-
The Evolution of a Scientist
A middle school student curious about science grows into a college-bound scientist.
-
Women in Science: Tania Small
Meet a Senior Medical Director at Novartis who is part of our new “Women in Science” series
-
New Orbis Flying Eye Hospital helps fight blindness in China
During a three-week maiden voyage to the northern city of Shenyang, the plane's medical volunteers treated 124 patients and provided hands-on surgical training to 18 local doctors.
-
Media ReleaseNovartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II studyProgression-free survival (PFS) in ALKi-naïve patients is consistent with results previously reported from Phase I ASCEND-1 study Phase II study also showed overall response rate of 63.3% in…
-
Media ReleaseNovartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow upLatest data confirm an estimated 45% of patients who received Tafinlar® + Mekinist® combination therapy are alive versus 31% of patients on BRAF monotherapy[1] Second trial to confirm three-year…
-
Media ReleaseNovartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of careLEE011 (ribociclib) plus letrozole reduced the risk of progression or death by 44% over letrozole alone, significantly extending progression-free survival (PFS) across all patient subgroups…
-
Chan Zuckerberg Initiative friends Novartis scientist in mission to conquer disease
Novartis’ Don Ganem tapped as a scientific advisor for the Chan Zuckerberg Biohub
-
Improving science communication in 3 easy steps
Pagination
- ‹ Previous page
- 1
- …
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- …
- 151
- › Next page